Thibaud Kössler, MD, PhD, on Localized Rectal Cancer: Neoadjuvant Pembrolizumab and Radiotherapy
2020 Gastrointestinal Cancers SymposiumThibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy in localized microsatellite-stable rectal cancer. The study explores whether a gene signature can predict sensitivity to immunotherapy (Abstract TPS272).
Related Videos
Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceed...
Thomas Yau, MBBS, on Advanced Hepatocellular Carcinoma: CheckMate 040 Trial of Nivolumab, Ipilimumab, and Cabozantinib
Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advance...
Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes
Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus ...
Zev A. Wainberg, MD, on PD-L1–Positive Advanced Gastric Cancer: MSI and Combined Positive Score and Pembrolizumab vs Chemotherapy
Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related...
Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool
Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cance...
